Salt and fluid intake is the first recommendation almost every POTS patient receives. Drink more. Eat more sodium. The rationale is correct as far as it goes: POTS is associated with reduced plasma volume, and expanding plasma volume reduces the venous return deficit when upright, which reduces the compensatory tachycardia. But Zouhal and colleagues' 2023 systematic review in Frontiers in Physiology establishes a second, independent pathway to plasma volume expansion — one that operates through a different mechanism than fluid intake and has different implications for how durable the volume benefit is. That pathway is exercise training, and the mechanism is not what most patients have been told.
The primary driver of exercise-induced plasma volume expansion is increased plasma protein content, specifically albumin. During and after sustained aerobic exercise, hepatic albumin synthesis increases. Albumin is an osmotically active protein — its oncotic pressure draws water from the interstitial compartment into the vascular space. More albumin in the plasma means more water pulled into the circulation. Plasma volume expands not because you drank more fluid but because the body has increased the osmotic capacity to retain fluid within the vascular compartment.
A secondary mechanism involves hormonal activation. Sustained exercise activates the renin-angiotensin-aldosterone system, signaling the kidneys to retain sodium. Retained sodium draws water into the bloodstream. This is a separate pathway from the albumin mechanism but acts in the same direction: both increase the volume of circulating fluid available to the cardiovascular system.
Critically, these mechanisms are independent of dietary sodium intake. The albumin oncotic mechanism responds to cardiovascular demand, not to fluid intake. A patient who is eating more salt but not exercising is attempting to expand plasma volume through only one of the available pathways. A patient who adds exercise — even recumbent exercise — activates a second pathway that operates even if dietary sodium is already maximized.
Zouhal's systematic review quantified the magnitude of plasma volume change across training protocols in different populations. Sedentary individuals beginning an endurance program typically achieve plasma volume increases of 10–20% within four to eight weeks, depending on training intensity and frequency. Competitive endurance athletes have plasma volumes 20–30% higher than sedentary controls of similar body size — a difference maintained by the training load rather than by any fixed characteristic of athletes themselves.
The detraining effect is equally well-documented. Within two to four weeks of stopping training, roughly half the plasma volume gained through training is lost. Within six to eight weeks of complete detraining, the expansion has largely reversed. The body eliminates what it is not required to maintain. This has direct clinical relevance for dysautonomia patients: plasma volume benefit accumulated through prior training does not persist through extended inactivity, and a period of reduced activity following a symptom flare represents a measurable volume loss that compounds the original condition.
For context: a 15% plasma volume increase in an average adult represents on the order of 400–500 mL of additional circulating fluid — fluid available to fill the heart before each beat and sustain venous return when upright. This is not a marginal effect. It materially changes the hemodynamic challenge of standing up.
When standing, approximately 500–700 mL of blood redistributes from the thorax into the lower extremities and splanchnic circulation under gravitational influence. The cardiovascular system compensates: the baroreflex detects the drop in central pressure and triggers vasoconstriction and heart rate increases to maintain perfusion. The adequacy of this compensation depends critically on having enough plasma volume to sustain venous return despite the peripheral pooling.
A person with reduced plasma volume begins the orthostatic challenge with less reserve. The same gravitational pooling that a person with normal volume compensates through modest adjustments may produce a significant drop in cardiac filling for someone who is already volume-depleted. The Raj et al. research on the renin-aldosterone paradox documented that many POTS patients have true plasma volume deficits — and that the hormonal signaling that should correct them is not functioning normally. In that context, exercise-driven albumin-mediated plasma expansion offers a pathway to volume restoration that does not depend on the same signaling cascade that is failing.
This is the mechanistic reason why exercise rehabilitation programs for POTS do not work simply by improving "fitness." The fitness benefit is secondary. The primary mechanism is plasma volume expansion reducing the venous return deficit that drives the compensatory tachycardia. Better cardiovascular conditioning is the outcome of the training; volume restoration is the mechanism.
The practical barrier is that the exercise forms most effective for plasma volume expansion — sustained upright aerobic activity — require orthostatic tolerance that many dysautonomia patients do not have. A patient whose heart rate reaches 130 bpm standing still cannot begin a walking program. This is where recumbent exercise protocols are not a compromise but a mechanistically sound first step.
Rowing machines, recumbent cycling, swimming, and resistance training performed in reclined positions apply the cardiovascular demand that activates the albumin synthesis pathway and the hormonal volume-retention mechanism without imposing the gravitational stress that exceeds the patient's current upright tolerance. The liver still receives the signals to increase albumin production. The RAAS is still activated. The plasma volume expansion mechanism operates. What changes is that the patient is not simultaneously trying to manage orthostatic hemodynamics while generating that exercise stimulus.
The evidence base for recumbent-first protocols in POTS rehabilitation — developed most extensively by the Dallas research group and in the Levine exercise protocol — consistently shows that patients who begin with recumbent exercise and progress to upright exercise as their tolerance builds achieve better outcomes than those who attempt upright exercise immediately. The logic is precisely what Zouhal's review describes: you are using exercise to expand the plasma volume that will, over weeks, expand the orthostatic tolerance that will eventually allow upright exercise.
Convertino's bed rest research established that plasma volume contracts by 10–15% within the first week of immobility in healthy subjects. For patients who have reduced activity due to symptoms, this detraining-induced volume loss is a secondary, additive contributor that compounds the original deficit. Zouhal's review establishes the dose-response for reversing it: consistent cardiovascular demand drives albumin synthesis and hormonal retention that expands plasma volume within weeks. The mechanisms are specific. The body responds reliably to this stimulus.
Exercise for dysautonomia is not an instruction to push through symptoms or overcome deconditioning through willpower. It is an application of a specific physiological mechanism — cardiovascular demand driving albumin-mediated plasma volume expansion — that addresses one of the measurable contributors to orthostatic tachycardia at its source. The right question is not whether to exercise but how to apply that demand without inducing the orthostatic stress that exceeds what the current hemodynamic system can manage. Recumbent protocols answer that question with the mechanism, not despite it.
Creative Commons CC BY 4.0 — Website by @autonomicdrama